ESSEX, Conn.--(

康涅狄格州埃塞克斯——（

BUSINESS WIRE

商业热线

)--Thetis Pharmaceuticals LLC (“Thetis”), a clinical-stage company developing TP-317, a first-in-class, small molecule drug candidate targeting the BLT1 receptor to treat inflammatory bowel disease (IBD), Crohn’s disease and ulcerative colitis, today announced that the company has secured an additional $8.975 million in program-related investment funding in the form of a loan from The Leona M.

)--Thetis Pharmaceuticals LLC（“Thetis”）是一家开发TP-317的临床阶段公司，TP-317是针对BLT1受体治疗炎症性肠病（IBD），克罗恩病和溃疡性结肠炎的一流小分子候选药物，今天宣布，该公司已获得Leona M。

and Harry B. Helmsley Charitable Trust (“Helmsley”), bringing Helmsley’s total program-related investment in support of oral applications of TP-317 as a potential therapy for Crohn’s Disease patients to $14,044,660. The newly approved funding will support a Phase 1b trial of TP-317 in ulcerative colitis patients to identify safe and efficient dosing..

和Harry B.Helmsley慈善信托基金（“Helmsley”），使Helmsley支持口服TP-317作为克罗恩病患者潜在疗法的总项目相关投资达到14044660美元。新批准的资金将支持TP-317在溃疡性结肠炎患者中的1b期试验，以确定安全有效的剂量。

Current treatment options for patients with Crohn’s disease, ulcerative colitis, and IBD fall short, with only a minority of patients achieving lasting remission. Effective therapy requires not only reducing inflammation but also actively repairing the intestinal lining to shield underlying tissues from harmful microbes and pro-inflammatory triggers.

克罗恩病，溃疡性结肠炎和IBD患者目前的治疗选择不足，只有少数患者达到了持久缓解。有效的治疗不仅需要减少炎症，还需要积极修复肠道衬里，以保护底层组织免受有害微生物和促炎触发因素的影响。

No currently approved therapy effectively addresses both therapeutic goals to achieve sustained remission. TP-317 is a proprietary compound of Resolvin E1 (RvE1), a naturally occurring lipid that engages the LTB4-BLT1 pathway to control inflammation and promote intestinal barrier integrity without compromising the body’s natural ability to fight infection..

目前没有批准的疗法有效地解决了两个治疗目标，以实现持续缓解。TP-317是Resolvin E1（RvE1）的专有化合物，这是一种天然存在的脂质，可通过LTB4-BLT1途径控制炎症并促进肠屏障完整性，而不会损害人体抵抗感染的天然能力。

“The Crohn’s Disease Program at Helmsley is dedicated to addressing the needs of people living with the disease by championing research and technologies that will improve care and treatment,” said Jessica Langer, Ph.D., Program Officer at Helmsley. “With a previous program-related investment in the form of a loan from Helmsley, Thetis successfully completed a Phase 1a study in healthy volunteers, demonstrating the favorable safety, tolerability, and pharmacokinetic profiles of TP-317.

赫尔姆斯利项目官员杰西卡·兰格博士说：“赫尔姆斯利的克罗恩病项目致力于通过支持能够改善护理和治疗的研究和技术来满足患有这种疾病的人的需求。”。“凭借之前以赫尔姆斯利贷款形式进行的项目相关投资，Thetis成功完成了健康志愿者的1a期研究，证明了TP-317具有良好的安全性，耐受性和药代动力学特征。

In this next phase, we hope to see evidence that TP-317 could expand treatment options and improve quality of life for people with IBD, including people with Crohn’s disease.”.

在下一阶段，我们希望看到证据表明TP-317可以扩大IBD患者（包括克罗恩病患者）的治疗选择并改善生活质量。”

“TP-317 offers a unique barrier protective mechanism that distinguishes TP-317 from existing therapies, with the potential to help IBD patients without the side effects associated with immune suppression,” said Bruce E. Sands, MD, MS, the Dr. Burrill B. Crohn Professor of Medicine, Icahn School of Medicine at Mount Sinai.

“TP-317提供了一种独特的屏障保护机制，将TP-317与现有疗法区分开来，有可能帮助IBD患者而不会产生与免疫抑制相关的副作用，”西奈山伊坎医学院医学博士Bruce E.Sands说。

Dr. Sands, a paid clinical advisor to Thetis, is also Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at the Mount Sinai Health System..

Sands博士是Thetis的付费临床顾问，也是西奈山卫生系统Henry D.Janowitz博士胃肠学部门的负责人。

“Helmsley has been remarkable in supporting our vision for a novel approach that addresses a critical unmet medical need in IBD,” said Gary Mathias, Co-Founder and Chief Executive Officer of Thetis. “We greatly appreciate their support and are excited to advance this unique therapy into patient studies.”.

Thetis联合创始人兼首席执行官加里·马西亚斯（GaryMathias）表示：“赫尔姆斯利（Helmsley）在支持我们提出一种新方法的愿景方面表现出色，该方法可以解决IBD中尚未满足的关键医疗需求。”。“我们非常感谢他们的支持，并很高兴将这种独特的疗法推进患者研究。”

About Thetis Pharmaceuticals

关于Thetis Pharmaceuticals

Thetis is a clinical-stage pharmaceutical company focused on developing innovative treatments for chronic inflammatory diseases and cancer. Its lead candidate, TP-317, is a first-in-class oral RvE1 drug candidate that targets the LTB4-BLT1 pathway to mobilize the body’s natural ability to resolve disease and restore immune homeostasis.

Thetis是一家临床阶段制药公司，专注于开发针对慢性炎症性疾病和癌症的创新疗法。其主要候选药物TP-317是一流的口服RvE1候选药物，其靶向LTB4-BLT1途径，以调动身体解决疾病和恢复免疫稳态的天然能力。

For more information, please visit .

有关更多信息，请访问。

www.thetispharma.com

www.thetispharma.com

, and follow us on

，并继续关注我们

LinkedIn

LinkedIn